Levodopa-Carbidopa Intestinal Gel may improve treatment-resistant freezing of gait in Parkinson’s disease

Shackleford, Melanie R; Mishra, Virendra; Mari, Zoltán

doi:10.1016/j.prdoa.2022.100148

Cited by 2 publications

(1 citation statement)

References 61 publications

(150 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Freezing of gait is a symptom that is often refractory to all current therapies in PD. In COSMOS, improvement in gait was observed [5] and this observation was supported in an extensive review of the existing literature [8]. While these data are not conclusive, further investigation of the effects of LCIG on gait seems warranted.…”

Section: Levodopa-carbidopa Intestinal Gelmentioning

confidence: 82%

Levodopa infusion therapies for Parkinson disease

Dean,

Standaert

2024

Current Opinion in Neurology

View full text Add to dashboard Cite

Purpose of review to review recent progress in the development and use of continuous levodopa therapies in Parkinson disease (PD). Recent findings Levodopa/Carbidopa intestinal gel (LCIG) is a continuous levodopa therapy which is widely used in the United States, Europe and other countries and is effective at reducing ‘off’ time. Recent work has shown that LCIG can be useful in managing dyskinesias and can improve nonmotor symptoms and quality of life. Several studies have shown good long-term effectiveness of LCIG. Recent data support the cost-effectiveness of this treatment strategy. Subcutaneous (SC) delivery of levodopa is a newer strategy that avoids the need for a surgically placed gastric tube. Two different products enabling SC delivery of levodopa are in development: ND0612 and foslevodopa/foscarbidopa. Both have recently been shown to reduce ‘off’ time in randomized, double-blind trials. Adverse effects of SC levodopa are primarily related to skin reactions at the infusion site. Summary Continuous levodopa therapies can be used to treat Parkinson disease motor fluctuations that cannot be managed with standard oral therapies. They may also improve nonmotor symptoms, and improve overall quality of life in patients with advanced PD.

show abstract

Section: Levodopa-carbidopa Intestinal Gelmentioning

confidence: 82%